TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26438533
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available flurbiprofen (FP) gel-type patch
Study: 17824582
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel with tretinoin microsphere (RAM) gel 0.04%
Study: 17824582
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel with tretinoin microsphere (RAM) gel 0.1%
Study: 17824582
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel with adapalene (AP) gel 0.1%
Study: 17824582
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel
Study: 17008436
Drug: Carbohydrate intake
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate intake before (approximately 150 g) and during exercise (1 g.kg body weight(‐1).h(‐1))
Study: 27146827
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet
Study: 8308768
Drug: Subcutaneous (sc)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (sc) injection
Study: 8308768
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet vs Oral solution
Study: 31792949
Drug: Naloxone 5
Normalized name: naloxone 5 mg/0.5 mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 5 μg.kg‐1.h‐1 infusion
Study: 27704631
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (3000 IU daily via oral spray)
Study: 23353579
Drug: computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: computerized cognitive behavioral therapy (cCBT) for insomnia
Study: 29076666
Drug: Topical Capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Capsaicin
Study: 3931509
Drug: Antihistamine
Normalized name: Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine
Study: 16723364
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg once daily)
Study: 12226033
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral treatment (amoxicillin, 1 g tid, or clarithromycin, 500 mg bid)
Study: 12226033
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of moxifloxacin and standard oral treatment
Study: 8073385
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral supplementation of alpha-tocopherol (825 mg daily), ascorbic acid (450 mg daily), and beta-carotene (45 mg daily) for three weeks prior to chemo- and radiotherapy.
Study: 8073385
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral supplementation of antioxidants prior to chemo- and radiotherapy (control group).
Study: 2643996
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg/day)
Study: 28260235
Drug: Exenatide once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide once-weekly (Bydureon™)
Study: 22111809
Drug: Bilateral distal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral distal implants with ball abutments (retentive anchors)
Study: 22111809
Drug: Bilateral distal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral distal implants with healing caps
Study: 15185466
Drug: Guideline-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based intervention (comprehensive education, prescribed diet, intensive pharmacological therapy)
Study: 31887369
Drug: Emricasan 5
Normalized name: Emricasán
DrugBank: Emricasan (DB05408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emricasan 5 mg
Study: 31887369
Drug: Emricasan 50
Normalized name: Emricasán
DrugBank: Emricasan (DB05408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emricasan 50 mg
Study: 31870950
Drug: Emricasan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emricasan (all doses)
Study: 28188024
Drug: Robotic-assisted gait
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted gait training therapy (RAGT) using Lokomat®Pediatric, 20 sessions
Study: 28188024
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group receiving only daily physiotherapy
Study: 15129731
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 g daily)
Study: 12771973
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (4 g daily)
Study: 8174729
Drug: Control sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control sperm preparation
Study: 8174729
Drug: Treated sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated sperm preparations
Study: 17945197
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) citalopram
Study: 17945197
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (SP) antagonist CP-96345
Study: 17945197
Drug: Glucocorticoid antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glucocorticoid antagonist RU486
Study: 10195530
Drug: Sameridine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sameridine 15 mg
Study: 10195530
Drug: Sameridine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sameridine 20 mg
Study: 10195530
Drug: Sameridine 23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sameridine 23 mg
Study: 8897012
Drug: GLP-1 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (50 pmol.kg‐1.h‐1) infusion
Study: 8897012
Drug: 154 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 154 mmol/l NaCl (placebo) infusion
Study: 10146956
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral therapy
Study: 6094455
Drug: Cefotaxime 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1.0 g
Study: 6205060
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g
Study: 3534018
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of etretinate
Study: 30922323
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of first-line therapy with oxaliplatin/fluoropyrimidine (control)
Study: 28488380
Drug: Capox (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capox (oxaliplatin 60 mg/m2 weekly with capecitabine 825 mg/m2 twice daily)
Study: 28488380
Drug: Cap (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap (capecitabine 825 mg/m2 twice daily)
Study: 25332100
Drug: Metformin (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (425 mg/d) for 24 months
Study: 21503849
Drug: Manual insertion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual insertion of mini-implants after pre-drilling with a dental handpiece
Study: 21503849
Drug: Self-drilling mini-implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-drilling mini-implants inserted without pre-drilling
Study: 21503849
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthetic next to the insertion region
Study: 21503849
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection methods
Study: 9256585
Drug: Parent-assisted social
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-assisted social skills training program (12 sessions); stimulant medication prescribed for all children with ADHD.
Study: 9256585
Drug: Waitlist group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist group (no treatment during the study period).
Study: 8500318
Drug: Topical ophthalmic
Normalized name: MIOTICS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic medications (specific medications not detailed)
Study: 25703254
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol plus 0.5 mg noretisterone acetate (NETA)
Study: 25703254
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg drospirenone (DRSP)
Study: 23010419
Drug: High Calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Calcium Diet (HCD; 1200-1300 mg/d)
Study: 23010419
Drug: Low Calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Calcium Diet (LCD; <500 mg/d)
Study: 17134031
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy for 1 week
Study: 17134031
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (diet therapy or oral hypoglycemic agents)
Study: 3492487
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg
Study: 9310011
Drug: Ciprofloxacin 1000
Normalized name: ciprofloxacin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1000 mg
Study: 973984
Drug: Isoniazid 300
Normalized name: isoniazid 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 300 mg
Study: 8443038
Drug: Ointment (radiolabelled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment (radiolabelled with technetium‐99m tin colloid)
Study: 8443038
Drug: 0.3% w/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% w/v HPMC solution (radiolabelled with technetium‐99m diethylenetriaminepentaacetic acid)
Study: 8443038
Drug: 0.3% w/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% w/v HPMC solution
Study: 31129911
Drug: Oral ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ticagrelor
Study: 28681435
Drug: Lenalidomide-based induction
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide-based induction therapy
Study: 23802768
Drug: Vemurafenib treatment
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib treatment in BRAF(V600E/K) advanced melanoma
Study: 21453882
Drug: 9mg budesonide
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9mg budesonide once daily (OD)
Study: 9862408
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (1 mg)
Study: 14967075
Drug: Docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel alone (30 mg/m2 weekly for 6 weeks)
Study: 14967075
Drug: Trastuzumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab alone (4 mg/kg intravenously on week 1 followed by 2 mg/kg per week thereafter)
Study: 14967075
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus docetaxel combination therapy
Study: 12651043
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg) + Aspirin (100 mg)
Study: 12651043
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg) + Aspirin (100 mg)
Study: 9084967
Drug: Topical glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glycopyrrolate
Study: 10319301
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of triamcinolone
Study: 1853956
Drug: Hydrochlorothiazide, 25
Normalized name: HydroCHLOROthiazide, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 25 mg b.i.d.
Study: 1853956
Drug: Furosemide, 20
Normalized name: Furosemide, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide, 20 mg b.i.d.
Study: 6193123
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection after preoperative chemotherapy
Study: 6193123
Drug: Limb-salvage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limb-salvage treatment
Study: 30134964
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) antagonist
Study: 20947591
Drug: Prilocaine 20
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prilocaine 20 mg and fentanyl 20 µg (Group P)
Study: 20947591
Drug: Bupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 7.5 mg and fentanyl 20 µg (Group B)
Study: 19723707
Drug: Three month
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three month occupational therapy and physiotherapy programme
Study: 15207440
Drug: Pet-therapy intervention
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pet-therapy intervention group (3/week sessions of almost one-hour visit for 6 weeks with a little cat)
Study: 28502060
Drug: EZ-blocker
Normalized name: Jock-Eze
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EZ-blocker
Study: 24550339
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of albendazole
Study: 24550339
Drug: Two-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose regimen compared to single-dose
Study: 24550339
Drug: Three-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose regimen compared to single-dose
Study: 22203049
Drug: 15-min neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-min neuromuscular warm-up programme carried out twice a week during the 11-week study period
Study: 15680715
Drug: Transcatheter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter treatment of ASA + PFO
Study: 12847496
Drug: Peanut butter
Normalized name: Zbar Peanut Butter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut butter skin contact (0.2 mL pressed flat for 1 minute)
Study: 12847496
Drug: Peanut butter
Normalized name: Zbar Peanut Butter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut butter inhalation (surface area of 6.3 square inches 12 inches from the face for 10 minutes)
Study: 12847496
Drug: Placebo (soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (soy butter mixed with histamine for contact, scent masked with soy butter, tuna, and mint for inhalation)
Study: 8909671
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion with spontaneous recovery
Study: 8909671
Drug: Neostigmine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.05 mg/kg and atropine 0.02 mg/kg
Study: 1498569
Drug: Norfloxacin ophthalmic
Normalized name: norfloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin ophthalmic solution
Study: 6739537
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg FK 33‐824
Study: 17382476
Drug: 40 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microg/kg rFVIIa administered at first skin incision and a second dose at 90 min later
Study: 11923489
Drug: Undiluted vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undiluted vaccine (10^7.8 pfu/ml)
Study: 11923489
Drug: 1:10 dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:10 dilution (10^6.5 pfu/ml)
Study: 11923489
Drug: 1:100 dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:100 dilution (10^5.0 pfu/ml)
Study: 9892064
Drug: Fluoxetine, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, a 5-HT uptake inhibitor, administered orally.
Study: 7634976
Drug: Rectally applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectally applied sulindac (53 mg/day average)
Study: 7634976
Drug: Rectally applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectally applied sulindac (67 mg/day average)
Study: 3548009
Drug: Butorphanol 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 4 mg
Study: 338393
Drug: Butorphanol 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 8 mg
Study: 7026254
Drug: Pentazocine 50
Normalized name: pentazocine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 50 mg
Study: 23936562
Drug: Antivenom treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivenom treatment
Study: 19303414
Drug: peginterferon alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alpha‐2a (180 microg once weekly)
Study: 16384840
Drug: RRR-alpha-tocopherol 400
Normalized name: RRR-alpha-tocopheryl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol 400 IU/day + ascorbic acid 500 mg/day (CEalpha)
Study: 16384840
Drug: RRR-alpha-tocopherol 290
Normalized name: RRR-alpha-tocopheryl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol 290 IU/day + RRR-gamma-tocopherol 130 IU/day + ascorbic acid 500 mg/day (CEalphagamma)
Study: 10694559
Drug: Soy tablets
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy tablets
Study: 8268142
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist and antacid (29 patients, H. pylori negative)
Study: 3512820
Drug: Intrauterine irrigation
Normalized name: Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine irrigation with cefazolin solution
Study: 3512820
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin administration
Study: 27221771
Drug: Orlistat-resveratrol combination
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat-resveratrol combination (O-R)
Study: 12382215
Drug: High-calorie and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie and high-protein blend formula (HP blend) or commercially available supplement (CNS) post-hemodialysis providing 500 kcal and 15 g protein for 1 month.
Study: 12382215
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received dietary monitoring and counseling but no specific post-HD supplement.
Study: 12382215
Drug: High-calorie and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie and high-protein blend formula (HP blend) or commercially available supplement (CNS) post-hemodialysis.
Study: 94266
Drug: creatinol O‐phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: creatinol O‐phosphate (COP) 1020 mg administered i.m. twice a day for 3 days
Study: 94266
Drug: reference substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: reference substance (solvent of COP) administered i.m. twice a day for 3 days
Study: 23796285
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of inpatient hospital treatment (HOSP)
Study: 23796285
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of inpatient treatment followed by 4 days of home treatment by community nurses (early assisted discharge)
Study: 21125215
Drug: 6 h
Normalized name: 1-36 hpthrp
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 h of normobaric oxygen therapy (NBO; arm A0)
Study: 22424025
Drug: Dalcetrapib 300
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 300 mg
Study: 25281277
Drug: Dalcetrapib 600
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 600 mg
Study: 21366361
Drug: Dalcetrapib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib (all doses)
Study: 17011712
Drug: d-amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0, 8, and 16 mg)
Study: 15262902
Drug: Fosinopril (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg)
Study: 11371412
Drug: Fexofenadine (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (180 mg doses over 14 h)
Study: 11371412
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg doses over 36 h)
Study: 14759451
Drug: Full-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose aprotinin
Study: 7539609
Drug: Half-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose aprotinin
Study: 8198266
Drug: Propofol 10
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 10 mg intravenously (i.v.)
Study: 29909435
Drug: Active PBMt
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PBMt (Photobiomodulation therapy)